Johnson & Johnson lost its latest effort to fend off Zytiga generics in court, sending investors reeling at the prospect of losing blockbuster sales. But the pharma giant says it’s now planning a last-ditch stand at the U.S. Supreme Court.
How much are pharma companies willing to pay in exchange for a faster trip to market in the U.K.? As it turns out, a cap of 2% on total branded-drug sales growth should do. And that’s a deal the industry is billing as a big savings for the government next
Teva has raised its annual earnings guidance as it reported a smaller-than-expected drop in profits for Q2, a good sign for the company's ongoing restructuring programme.